Clinical Trials Logo

Clinical Trial Summary

Shwachman-Diamond syndrome (SDS) is a genetic condition characterized by bone marrow failure, medical co-morbidities, and leukemia predisposition. SDS-Like patients share clinical features with SDS but lack mutations in known SDS genes. Since SDS/SDS-Like syndromes are rare diseases, data are sparse regarding the clinical features, natural history, clinical outcomes with current management, and treatment. For this reason, the SDS Registry was formed to collect clinical data from medical records and to bank biological samples with the goal of understanding SDS/SDS-Like diseases to develop better treatments and improve the health of patients with these conditions.


Clinical Trial Description

The Shwachman-Diamond Syndrome Registry (SDSR) is dedicated to accelerating research and treatment for SDS to improve survival and quality of life for all patients with the disease. The SDSR is run jointly by Boston Children's Hospital and Cincinnati Children's Hospital Medical Center. Objective and Aims: The long term goals of the Registry are to improve diagnosis, inform medical management, and to develop better treatments for SDS and SDS-Like disorders. To achieve these objectives, the Registry has the following specific aims: - Characterize the natural history, medical complications, and treatment outcomes for patients with SDS and SDS-Like disorders. - Investigate the molecular and genetic pathogenesis of SDS/SDS-Like conditions and their complications such as marrow failure and clonal evolution. - Identify new genes causing SDS/SDS-Like conditions. - Provide education on the diagnosis, medical management and treatment of SDS for patients, families and the medical/scientific community. Methods: The SDSR collects information from medical records and biological samples. Samples for the SDSR are collected when they are obtained for clinical care so that no extra visits or procedures are needed. These samples may include blood, bone marrow, skin cells, saliva, or discards from other clinical procedures. Family members may also contribute blood samples. All information obtained by the SDSR is housed on a secure, HIPAA-compliant database. No personal information is shared outside of the study team. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06056908
Study type Observational [Patient Registry]
Source Boston Children's Hospital
Contact Akiko Shimamura, MD, PhD
Email akiko.shimamura@childrens.harvard.edu
Status Recruiting
Phase
Start date January 19, 2016
Completion date January 1, 2090

See also
  Status Clinical Trial Phase
Recruiting NCT02179359 - Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT00176852 - Stem Cell Transplant for Hemoglobinopathy Phase 2/Phase 3
Completed NCT00176878 - Stem Cell Transplant for Bone Marrow Failure Syndromes Phase 2/Phase 3
Completed NCT01917708 - Bone Marrow Transplant With Abatacept for Non-Malignant Diseases Phase 1
Completed NCT00499070 - Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment N/A
Recruiting NCT04275479 - Diabetes/ Endocrine Surveillance in SDS
Completed NCT01529827 - Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Active, not recruiting NCT03333486 - Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Phase 2
Recruiting NCT04965597 - Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) Phase 2